Please login to the form below
Acacia Pharma
This page shows the latest Acacia Pharma news and features for those working in and with pharma, biotech and healthcare.
Acacia finally gets FDA okay for first product Barhemsys
Edison analyst predicts drug could reach $387m at peak. The long tale of Acacia Pharma’s efforts to bring its post-operative nausea and vomiting (PONV) drug Barhemsys to market is ... sedation. It licensed the drug from Cosmo Pharma in a deal that also
Latest news
-
Acacia eyes February FDA verdict for refiled nausea drug Barhemsys
Back on track after being turned down twice. Acacia Pharma’s experimental drug for post-operative nausea and vomiting (PONV) looks back on track, after being turned down twice by the ... Acacia’s Euronext-listed shares rose almost 3% on news of the
-
UK biotech booms in 2018, despite Brexit worries
There were just five initial public offering (IPOs) in the year, raising £432m, with another £658m coming from follow-on public financings, including a £273m round from GW Pharma. ... 2018’s UK IPOs came fromSensyne Health, Acacia Pharma and
More from news
Approximately 2 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
- Account Manager, 6 month contract, Healthcare Brand communicatio...
- Highly competitive salary
- Account Manager, Healthcare Marketing Creative Agency, Fixed ter...
- Highly competitive salary
- Market Access Director, six figure base salary and £5K joining b...
- Highly competitive salary
- Senior Medical Copywriter - Highly Awarded Advertising Agency
- £50,000 - £60,000 yearly
- Home Based Account Manager, Medical Communications, UK, Pharma/M...
- Highly competitive salary
- Account Director, Healthcare Marketing Creative Agency, Fixed te...
- Highly competitive salary
- AbbVie’s Rinvoq receives FDA approval for Crohn’s disease
- Bayer’s Nubeqa combination recommended by NICE to treat metastatic prostate cancer
- AstraZeneca announces positive phase 3 results for Tagrisso combination in lung cancer
- Bristol Myers Squibb presents positive results for idiopathic pulmonary fibrosis drug
- FDA approves Blueprint Medicines’ Ayvakit for indolent systemic mastocytosis
- Novo Nordisk announces positive phase 3 results for oral weight-loss drug
- Medscape Medical Affairs Selected as Finalist for 2023 Communiqué Awards
- COVID-19: Pfizer’s Paxlovid approved by FDA and Gilead’s Veklury recommended by CHMP
- BMS and Janssen’s antithrombotic granted FDA fast track designation
- Gene therapy, gene editing and perspectives on future use in Parkinson’s disease
- Patient Clinical Trial & Communications Plan Review: A Customer Story
- Shining a Spotlight on Women’s Health Education Outcomes at ACOG 2023
PMHub
Apex.co.uk Events and Exhibition Stands
Apex.co.uk is one of the UK’s leading exhibition stand and event agencies, specialising in healthcare. We understand your communication goals,...
Latest intelligence
- Patient Clinical Trial & Communications Plan Review: A Customer Story
- ...
- Working together to achieve better patient pathways
- Digital tools can supercharge patient treatment and outcomes but the importance of the patient voice cannot be underestimated...
- Design-thinking. Iterating for continuous improvement.
- How design can lead improvement within Pharma...
